Your browser doesn't support javascript.
loading
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.
Xu, Jian Ming; Wang, Yan; Chen, Yu Ling; Jia, Ru; Li, Jie; Gong, Ji Fang; Li, Jing; Qi, Chuan; Hua, Ye; Tan, Cui Rong; Wang, Jian; Li, Ke; Sai, Yang; Zhou, Feng; Ren, Yong Xin; Qing, Wei Guo; Jia, Hong; Su, Wei Guo; Shen, Lin.
Afiliación
  • Xu JM; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
  • Wang Y; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
  • Chen YL; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
  • Jia R; Department of Gastrointestinal Oncology, The Affiliated Hospital Cancer Center (The 307th Hospital of Chinese People's Liberation Army), Academy of Military Medical Sciences, Beijing, China.
  • Li J; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
  • Gong JF; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
  • Li J; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
  • Qi C; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
  • Hua Y; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
  • Tan CR; Clinical and Regulatory Department, Hutchison MediPharma Limited, Shanghai, China.
  • Wang J; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
  • Li K; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
  • Sai Y; Drug Metabolism and Pharmacokinetic Department, Hutchison MediPharma Limited, Shanghai, China.
  • Zhou F; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
  • Ren YX; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
  • Qing WG; Oncology Department, Hutchison MediPharma Limited, Shanghai, China.
  • Jia H; Chemistry Department, Hutchison MediPharma Limited, Shanghai, China.
  • Su WG; Chemistry Department, Hutchison MediPharma Limited, Shanghai, China.
  • Shen L; Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
Oncotarget ; 8(26): 42076-42086, 2017 Jun 27.
Article en En | MEDLINE | ID: mdl-28159938
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article